-
Posted by
Two Blokes Jul 7 -
Filed in
Stock
-
4 views
Wave Life Sciences Ltd. is an innovative biotech with soli data for its AATD, Huntington's, and DMD programs. Its share price is nevertheless down 44% year-to-date, potentially creating a buying opportunity for a risk-on investor. Wave is partnered with GSK over its AATD program which recently demonstrated proof-of-concept and opens up the possibility of triple-digit million milestone payments.
